Interferon gamma induction in human melanoma cell/allogeneic leukocyte co-cultures is enhanced by interleukin 18 but drug resistant melanoma cells are poorer inducers of IFN-gamma.

[1]  J. Naeyaert,et al.  Understanding the trends in melanoma incidence and mortality: where do we stand? , 2000, European journal of dermatology : EJD.

[2]  A. Eggermont,et al.  The Emerging Role of Cytokines in the Treatment of Advanced Melanoma , 2000, Oncology.

[3]  P. Queirolo,et al.  Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. , 1999, Anticancer research.

[4]  M. Micallef,et al.  Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model , 1999, Cancer Immunology, Immunotherapy.

[5]  S. Melnick,et al.  Multidrug resistance in human tumors--molecular diagnosis and clinical significance. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.

[6]  M. Hirose,et al.  Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. , 1999, Journal of immunotherapy.

[7]  M. Micallef,et al.  Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration , 1999, Cancer Gene Therapy.

[8]  C. Ioannides,et al.  Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. , 1998, Cancer research.

[9]  A. Bhushan,et al.  Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95) , 1998, Immunology and cell biology.

[10]  R Khanna,et al.  Tumour surveillance: Missing peptides and MHC molecules , 1998, Immunology and cell biology.

[11]  T. Grogan,et al.  Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins , 1997, Leukemia.

[12]  A. Krishan,et al.  Flow cytometric analysis of the multiple drug resistance phenotype , 1997, Leukemia.

[13]  H. Okamura,et al.  Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Tanimoto,et al.  Interferon‐γ‐inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin‐12 for interferon‐γ production , 1996 .

[15]  H. Okamura,et al.  Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. , 1996, Journal of immunology.

[16]  H. Okamura,et al.  Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.

[17]  T. Tanimoto,et al.  Interleukin 18 induces a synergistic enhancement of interferon gamma production in mixed murine spleen cell-tumor cell cultures: role of endogenous interleukin 12. , 2000, Cancer detection and prevention.

[18]  R. Johnstone,et al.  Multiple physiological functions for multidrug transporter P-glycoprotein? , 2000, Trends in biochemical sciences.

[19]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[20]  J. Wharton,et al.  Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. , 1994, Lymphokine and cytokine research.

[21]  M. Poupon,et al.  Drug-induced tumor progression in a rat rhabdomyosarcoma. , 1988, Advances in experimental medicine and biology.